LGND
Ligand Pharmaceuticals Incorporated
301.50$
+0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 10.6% | 5.9% | 35.7% | -36.9% | 24.1% | 6.6% | 10.7% | 6.1% | 21.5% | -43.6% | 4.0% | 5.0% | 1.4% | |
| 89.4% | 94.1% | 64.3% | 136.9% | 75.9% | 93.4% | 89.3% | 93.9% | 78.5% | 143.6% | 96.0% | 95.0% | 98.6% | |
| 16.8% | 19.5% | 19.3% | 12.9% | 11.0% | 10.3% | 110.5% | 13.8% | 18.2% | 5.9% | 4.2% | 23.0% | 14.2% | |
| 44.6% | 56.9% | 35.4% | 42.4% | 47.2% | 59.8% | 41.5% | 42.4% | 24.6% | 41.9% | 40.3% | 45.7% | 35.6% | |
| 80.0% | 106.0% | 54.6% | 182.9% | 69.8% | 115.9% | 169.2% | 76.2% | 30.9% | 110.0% | 62.4% | 81.5% | 63.8% | |
| 9.4% | -11.9% | 9.6% | -46.0% | 6.1% | -22.5% | -79.9% | 17.7% | 47.6% | 33.6% | 33.6% | 13.5% | 34.7% | |
| 0.0% | 0.5% | 0.5% | 3.1% | 1.4% | 2.1% | 1.9% | 2.4% | 0.8% | 3.0% | 3.4% | 2.7% | 2.1% | |
| -36.9% | 60.8% | 366.2% | -157.4% | -12.2% | -91.6% | -110.7% | 23.6% | 122.2% | 95.2% | -46.9% | 101.0% | 81.9% | |
| -5.7% | -3.9% | 88.2% | -32.5% | 1.6% | -18.9% | -17.0% | 13.4% | 20.7% | 20.1% | -21.1% | 24.8% | 14.0% | |
| -31.3% | 64.7% | 278.1% | -125.0% | -13.8% | -72.6% | -93.6% | 10.2% | 101.6% | 75.1% | -25.8% | 76.2% | 67.9% | |
| -10.7% | 93.1% | 395.0% | -133.1% | 6.6% | -69.3% | -89.4% | 43.9% | 129.2% | 111.3% | -27.6% | 113.7% | 94.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.